Natera (NASDAQ:NTRA) Insider Sells $479,970.00 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $159.99, for a total value of $479,970.00. Following the sale, the insider owned 117,559 shares in the company, valued at approximately $18,808,264.41. The trade was a 2.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, September 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $166.62, for a total value of $499,860.00.
• On Thursday, August 14th, Solomon Moshkevich sold 875 shares of Natera stock. The stock was sold at an average price of $155.46, for a total value of $136,027.50.
• On Friday, August 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $132.89, for a total transaction of $398,670.00.
• On Monday, July 28th, Solomon Moshkevich sold 2,206 shares of Natera stock. The shares were sold at an average price of $139.81, for a total transaction of $308,420.86.
• On Monday, July 21st, Solomon Moshkevich sold 291 shares of Natera stock. The stock was sold at an average price of $139.29, for a total transaction of $40,533.39.

Natera Trading Up 4.5%

NTRA opened at $167.35 on Friday. The company has a fifty day moving average price of $161.17 and a two-hundred day moving average price of $156.61. Natera, Inc. has a 1-year low of $117.27 and a 1-year high of $183.00. The company has a market cap of $22.97 billion, a P/E ratio of -87.62 and a beta of 1.74.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The firm had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. During the same quarter in the prior year, the business earned ($0.30) earnings per share. The business’s quarterly revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. On average, research analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NTRA has been the subject of several recent research reports. Wells Fargo & Company started coverage on Natera in a report on Monday, September 22nd. They set an “equal weight” rating and a $175.00 price target for the company. Stephens reissued an “overweight” rating and issued a $183.00 target price on shares of Natera in a research report on Friday, August 15th. Royal Bank Of Canada set a $268.00 price target on shares of Natera and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Evercore ISI upgraded shares of Natera to a “strong-buy” rating and set a $170.00 price objective for the company in a research report on Monday, July 28th. Finally, Piper Sandler reissued an “overweight” rating and set a $220.00 price objective (up previously from $210.00) on shares of Natera in a report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $192.88.

Hedge Funds Weigh In On Natera

Several large investors have recently modified their holdings of NTRA. Vanguard Group Inc. grew its holdings in Natera by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock valued at $2,141,594,000 after purchasing an additional 282,826 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Natera by 44.3% during the second quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock valued at $1,795,125,000 after acquiring an additional 3,263,822 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Natera by 56.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock worth $1,490,144,000 after buying an additional 3,795,315 shares during the last quarter. Geode Capital Management LLC lifted its position in Natera by 7.0% during the 2nd quarter. Geode Capital Management LLC now owns 2,552,725 shares of the medical research company’s stock worth $430,640,000 after acquiring an additional 166,768 shares during the period. Finally, Invesco Ltd. boosted its position in Natera by 13.7% in the first quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company’s stock valued at $287,908,000 after buying an additional 245,719 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.